Duocarmycin‐Bearing Antibody‐Mimetic Drug Conjugate Combined With an ATR Inhibitor Results in Complete Tumor Regression in a KPL ‐4 Xenograft Model
Cancer Medicine · 2026-07 · 15 (7)
DOI: 10.1002/cam4.72071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 06.07.2026. Verfasst von Toshiya Tanaka und 24 weiteren Autor:innen. Beteiligte Einrichtung: Laboratories for Systems Biology and Medicine (LSBM) at Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Meguro-…. Hauptthemen laut MEDLINE: Ataxia Telangiectasia Mutated Proteins, Immunoconjugates, Indoles, Breast Neoplasms. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Mochida Memorial Foundation for Medical and Pharmaceutical Research.
Abstract (Originalsprache)
Antibody–drug conjugates (ADCs) have demonstrated superior clinical outcomes in patients with HER2‐positive advanced breast cancer compared with previous treatment modalities. However, resistance and treatment‐limiting toxicities frequently emerge during repeated administration, underscoring an unmet need for strategies to overcome ADC failure. In this study, we investigated whether inhibition of ataxia telangiectasia and Rad3‐related protein (ATR) could enhance the antitumor efficacy of antibody‐mimetic drug conjugates (AMDCs), a targeted payload delivery platform. Combination treatment with a duocarmycin‐bearing HER2‐targeted AMDC (Duo‐HER2) and an ATR inhibitor markedly enhanced antitumor activity in a human HER2‐positive breast cancer xenograft model. In a limited cohort of treated mice, this combination induced sustained tumor suppression, with prolonged tumor‐free survival exceeding 100 days. Although transient body weight loss was observed during the early phase of treatment, no evidence of overt systemic toxicity was detected. Synergistic interactions with Duo‐HER2 were further confirmed in vitro using three clinically relevant ATR inhibitors—tuvusertib, ceralasertib, and berzosertib. Short‐term apoptosis analyses revealed only modest induction of cell death, whereas longer‐term viability assays demonstrated pronounced growth suppression. Cell cycle analyses showed S‐phase accumulation accompanied by a mild increase in the sub‐G1 population, suggesting that the combination initially exerts a cytostatic effect through replication stress–induced S‐phase arrest, followed by delayed cytotoxicity. Together, these findings indicate that Duo‐HER2 combined with ATR inhibitors synergistically suppresses tumor growth in HER2‐positive breast cancer models. Further studies employing optimized formulations, expanded in vivo cohorts, and additional tumor models will be required to fully define the therapeutic potential of this strategy and its relevance for overcoming ADC resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratories for Systems Biology and Medicine (LSBM) at Research Center for Advanced Science and Technology (RCAST), The University of Tokyo, Meguro-ku, Japan.
- Division of Drug Discovery and Medical Device Development, Institute for Biomedical Sciences of Iwate Medical University, Shiwa-gun, Japan.
- Isotope Science Center, The University of Tokyo, Bunkyo-ku, Japan.
- CompleCure, Inc, Shibuya-ku, Japan.
- Department of Clinical Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Science, Hoshi University, Shinagawa-ku, Japan.
- Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
ORCID-Profile: Toshiya Tanaka, Akira Sugiyama, Hiroto Katoh, Tsuyoshi Osawa, Shumpei Ishikawa, Kenzo Yamatsugu, Motomu Kanai
Förderung
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
- Kobayashi Foundation for Cancer Research
- Takeda Science Foundation
Zitieren
APA
Tanaka, T., Sugiyama, A., Sakata, J., Tatsumi, T., Katoh, H., Maeda, K., Inagaki, Y., Yamashita, T., Kawamura, T., Kuratani, M., Nakano, T., Ishii, M., Miura, M., Kamiya, W., Shiratori, Y., Kitanoya, H., Chansler, M., Harada, N., Tsuchiya, M., …, & Kanai, M. (2026). Duocarmycin‐Bearing Antibody‐Mimetic Drug Conjugate Combined With an ATR Inhibitor Results in Complete Tumor Regression in a KPL ‐4 Xenograft Model. Cancer Medicine, 15(7). https://doi.org/10.1002/cam4.72071
Vancouver
Tanaka T, Sugiyama A, Sakata J, Tatsumi T, Katoh H, Maeda K, et al. Duocarmycin‐Bearing Antibody‐Mimetic Drug Conjugate Combined With an ATR Inhibitor Results in Complete Tumor Regression in a KPL ‐4 Xenograft Model. Cancer Medicine. 2026;15(7). doi:10.1002/cam4.72071
BibTeX
@article{Tanaka2026,
author = {Tanaka, Toshiya and Sugiyama, Akira and Sakata, Juri and Tatsumi, Toshifumi and Katoh, Hiroto and Maeda, Keisuke and Inagaki, Yuya and Yamashita, Takefumi and Kawamura, Takeshi and Kuratani, Mayu and Nakano, Taiki and Ishii, Masazumi and Miura, Mai and Kamiya, Wakana and Shiratori, Yuko and Kitanoya, Hisato and Chansler, Michael and Harada, Naoki and Tsuchiya, Masayuki and Osawa, Tsuyoshi and Ishikawa, Shumpei and Kodama, Tatsuhiko and Yamatsugu, Kenzo and Tokuyama, Hidetoshi and Kanai, Motomu},
title = {Duocarmycin‐Bearing Antibody‐Mimetic Drug Conjugate Combined With an ATR Inhibitor Results in Complete Tumor Regression in a KPL ‐4 Xenograft Model},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {7},
doi = {10.1002/cam4.72071}
}
EUVIMED